Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 January 2019 | Story Charlene Stanley | Photo Charlene Stanley
Michele Middle
Michelle Middle, CMO of Farmovs, looks forward to expanding their operations after the UFS acquired 100% shareholding in 2018.

In medical research, there are NO shortcuts.

The journey of a new medicine from lab to pharmacy shelf takes on average at least 10 years.

Michelle Middle’s journey from young medical graduate starting her first job at FARMOVS to becoming the company’s Chief Medical Officer, was more than twice that long. It was a journey that systematically and adequately equipped her to now Co-captain this flagship enterprise through its biggest challenge yet.

Michelle remembers how Farmovs started in 1974 as a research centre in the Department of Pharmacology. After graduating as medical doctor, she joined Farmovs in 1993, shortly before they moved to their current extensive facilities just south of the Sasol Library.

In 2000, international Clinical Research Organization (CRO) giant Parexel acquired a 70% shareholding, and the name changed to Farmovs-Parexel.

“Parexel really invested a lot in infrastructure and technology, bringing facilities here on par with the best in the world,” says Michelle.

Her own journey in medical research took her to George and later to the US and UK, where she held various international executive leadership positions in international companies.

When the UFS acquired a 100% shareholding in Farmovs earlier this year, she came full circle, as she returned to Bloemfontein to spearhead the expansion of patient studies in collaboration with the Faculty of Health Sciences.

“The opportunities we have here are really enormous,” says an excited Michelle.

“We are the only university in the country with this kind of infrastructure. Apart from our state-of-the-art bioanalytical lab, we also have facilities to accommodate close to 100 research participants. We now have 45 years’ experience in advanced medical research, plus established international clients. We can provide pharmaceutical companies with basically everything they need to develop new medicines.”

Another exciting development is that they are expanding their clinical-trial patient population next year from healthy individuals to people suffering from a host of chronic conditions.

“While they are part of our clinical trials, patients gain valuable insight in their own conditions. We also sometimes pick up underlying medical issues they were not even aware of,” says Michelle.

The 150 Farmovs staff members range from doctors and nurses, to technologists, medical writers, and managers. While not technically part of the university staff, they form a valued part of the Bloemfontein Campus community.

News Archive

Free State Receives R7 Million Grant from the Mellon Foundation for Arts Innovation
2015-11-30


Man in the Green Blanket, Lesiba Mabitsela.
Photo: Karla Benade

Bloemfontein will experience a flood of new, experimental art over the next four years as a result of R7 million that has been received to develop experimental art projects in central South Africa. The Andrew W. Mellon Foundation recently awarded the grant to the University of the Free State (UFS) for the Programme for Innovation in Artform Development (PIAD). Initiated jointly by the UFS and the Vrystaat Arts Festival in 2014, PIAD was established as a programme to promote the exploration of the arts to advance interdisciplinary research and to impact on human development.

The Andrew W. Mellon Foundation is a New York-based, non-profit organisation which endeavours to strengthen, promote, and, where necessary, defend the contributions of the humanities and the arts to human flourishing, and to the well-being of diverse and democratic societies.

“The Innovation in Artform Development initiative will provide an important contribution to the ways in which the university hopes to broaden and deepen research and dialogue about the humanities in South African society. Using the arts as a vehicle to engage communities around issues of social significance, makes for an exciting endeavour, and we are happy to have Mellon’s financial and partnership investment in this initiative,” said Prof Jonathan Jansen, Vice-Chancellor of the UFS.

“This substantial support from the Foundation will play a pivotal role in facilitating collaborations with national and international artists to explore new, innovative modes of artistic practice and creative production in South Africa,” said Angela de Jesus, UFS Art Curator and Co-Director of PIAD.

“A series of First Nations projects, arts/science research and artist residencies, arts laboratories for creative practitioners, the production of exciting new work for Bloemfontein, and critical debates/forums is expected over the next few years,” she added.

PIAD focuses on supporting cross-cultural, experimental art programmes that can assist South African society creatively. For this process, PIAD is engaging the skills and expertise of South Africa artists in collaboration with several international partners, who are recognised as global leaders in this field, to develop a mutually- beneficial programme of engagement.  

Innovation, technology, and new forms of art will be explored and international collaborations that have the potential to attract benefits for the creative industries in Bloemfontein and beyond will be introduced.

“The artistic landscape of the Free State - in fact the whole South Africa - will be forever changed because of this extraordinarily generous grant. Rarely does a regional community get a chance to lead innovation on a national scale, and also impact on experimental art internationally. We are in for an incredible artistic journey,” said Dr Ricardo Peach, Director of the Vrystaat Arts Festival and Co-Director of PIAD.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept